Resolution of Medical Issues through Products and Services

Offering Superior Technologies to Help Eliminate Malaria

Recognition of the Social Issue

Malaria is one of the world’s three major infectious diseases. Although the number of infections and deaths due to malaria has been falling for the past several years, annually around 200 million people are infected and some 450,000 die from the disease. In Africa, one child under the age of five dies from malaria every two minutes*.

The Sustainable Development Goals (SDGs) adopted by the United Nations in 2015 address a number of medical issues, and the World Health Organization (WHO) has set the goal of cutting malaria-related deaths, and the number of people infected by the disease, by 90% by 2030, compared with 2015 levels.

* Source: World Malaria Report 2017

Malaria Infections and Deaths

Malarial infections
per year

200 million

Deaths per year


Sysmex’s Policy on Addressing Medical Issues

Sysmex has identified the “resolution of medical issues through products and services” as a priority issue (materiality item) with a view to realizing a sustainable society and achieving sustainable growth for the Company. By leveraging our technologies, we aim to contribute toward measures to fight the three major infectious diseases in the IVD field.

Malarial Infections Globally

Malarial Infections Globally

Relation to the SDGs

The Sustainable Development Goals (SDGs) adopted by the United Nations consist of 17 goals to be met by 2030. Goal 3, to “Ensure healthy lives and promote well-being for all at all ages,” targets the following objectives.

  • Reduce maternal mortality
  • Reduce the mortality of newborns and children under five years of age
  • Eradicate AIDS, tuberculosis, malaria and tackle other communicable diseases
  • Reduce premature mortality from non-communicable diseases
  • Ensure access to essential healthcare services, medicines and vaccines
  • Develop the skills of, and conduct training for, health workers in developing countries
Comment from a Stakeholder

Kiyoshi Kita School of Tropical Medicine and Global Health Dean, Professor

Kiyoshi Kita
Nagasaki University
School of Tropical
Medicine and Global Health
Dean, Professor

Partnership Aimed at Overcoming Tropical Infectious Diseases Not Present in Japan

We have succeeded in eradicating malaria in Japan; nobody in this country is infected. Overseas, however, the situation remains largely unchanged. With the emergence of drug-resistant malarial plasmodia and insecticide-resistant mosquitos, in some countries the number of infections and deaths have actually increased. Changing this situation and protecting from malaria the children who represent the future of the world requires a well-concerted, three-pronged approach: prevention, diagnosis and treatment. I find it very encouraging that Sysmex and other Japanese companies that aim to contribute to global health are taking the lead in a consortium to eliminate malaria through superior tools and specific strategies. I have great expectations for the success of this effort and its subsidiary benefits.

Specific Initiatives for Eliminating Malaria

Developing Products to Help Eliminate Malaria

Sysmex has developed and begun selling1 the XN-30 multi-parameter automated hematology analyzer, which allows the detection of blood infections from malarial plasmodia.

As well as measuring infected red blood cell parameters such as malarial plasmodia2, the XN-30 provides information indicating the quantity of infected red blood cells and the type of malarial plasmodia present. This information is important, as the treatment method generally varies depending on the type of malarial plasmodia. We are also working on technologies to identify asymptomatic carriers—people who have malarial plasmodia in their bodies but do not have the illness themselves—as addressing this situation is considered one way of preventing the spread of the infection.

The XN-30 is being used for basic research. The Research Institute for Microbial Diseases at Osaka University is using this instrument in an effort to discover new anti-malarial drugs.

In addition to our next model, which will feature certain improvements, going forward we will seek to obtain regulatory approval in various countries so that the instrument can be used in laboratories and other clinical facilities.

1 In Japan only

2 Research parameter

XN-30 Features

XN-30, XN Series multiparameter automated hematology analyzer

XN-30 multiparameter automated hematology analyzer


  1. Fast (measurement in approximately 1 minute)
  2. Simple and accurate
    No need for the technical skills required for conventional testing by microscope
  3. Highly sensitive
    Capable of measuring malarial plasmodia and other infected red blood cells at concentrations of 20cells/μL

Promoting a Partnership to Eliminate Malaria

Such worldwide issues as malaria cannot be resolved by a single company. Rather, it calls for strong partnerships that leverage the strengths of industry, the government, and academia, as well as nonprofit organizations and local communities.

Since 2016, Sysmex has been participating in the Malaria Consortium, a joint effort between industry, government, and academia. We are taking on a role in the field of blood testing.

The Malaria Consortium proposed "P3 (Public -Private Partnership) from Japan for Malaria Elimination" in Asia and Africa to the Japanese government in April 2018. It aims at malaria elimination by combining Japanese companies' technologies.

Malaria Consortium Initiatives

Malaria Consortium Initiatives

  • Develop insecticide-treated mosquito nets, sprays and mosquito-repellant paint
  • Develop infection-preventing drugs
  • Provide health guidance
  • Gene testing
  • Blood testing: Sysmex’s role
  • Develop drugs for treatment